Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study
Anti-IL-23 therapies are effective in achieving and sustaining PASI 100 in routine care. Outcomes are influenced by disease localization, duration, prior treatments, and baseline severity. Limitations include retrospective design, single-center setting, and absence of comparators.
Authors
- Salvatore Panduri (ORCID: https://orcid.org/0000-0003-1383-498X)
- Giorgia Salvia (ORCID: https://orcid.org/0000-0002-5967-6692)
- Alessandra Michelucci (ORCID: https://orcid.org/0000-0002-0795-0338)
- Flavia Manzo Margiotta (ORCID: https://orcid.org/0000-0002-9593-9357)
- Marco Romanelli (ORCID: https://orcid.org/0000-0002-4127-0141)
- Valentina Dini (ORCID: https://orcid.org/0000-0002-4639-3167)
- Riccardo Morganti (ORCID: https://orcid.org/0000-0001-7783-0262)
- Nicolò Mori (ORCID: https://orcid.org/0009-0002-0721-9542)
- Simone Sturli
Institutions
- University of Pisa (IT)
- Scuola Superiore Sant'Anna (IT)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/14712598.2025.2584387
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00